ClinicalTrials.gg
Not yet recruitingNCT05839132Updated May 3, 2023

Clinical Effect of Acupuncture in Neurodegenerative Diseases on Traumatic Brain Injury Patients

An interventional study of Acupuncture in Neurodegenerative Diseases, sponsored by China Medical University Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 20 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-03.

Sponsored by China Medical University Hospital · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
76
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Neurodegenerative Diseases with a site in Taiwan — 4 open to participants now, 6 under way, 2 of them phase 3. Neurodegenerative Diseases · Taiwan.

Planned enrollment
9th of 12
76 · median 212
Started
2023
the only one that year
No phase
3 of 13
2 open now
Registered
7th of 13
by date
Lead sponsor
1 of 13
China Medical University Hospital

Among the 13 studies in Neurodegenerative Diseases with a site in Taiwan, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 3 with no phase, and was the 7th registered.

Neurodegenerative Diseases

436 studies on the registry are indexed under Neurodegenerative Diseases; 143 are open to participants now.

Browse Neurodegenerative Diseases studies →

Open to participants now

4 of the 13 studies in Neurodegenerative Diseases with a site in Taiwan are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 101 Neurodegenerative Diseases studies recruiting now, 52 (51%) set no upper age limit and 11 (11%) stop at 75 or younger; 20 take children under 18; 49 take healthy volunteers.

This study: 20 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Neurodegenerative Diseases with a site in Taiwan, or all of them as a file.
02

Study summary

Traumatic brain injury (TBI) is an altered brain function caused by an external force, which may annually have 69 million incidence cases all over the world. Increasing evidence suggests that TBI may be a major risk of beta amyloid (Aβ)-associated neurodegenerative disorders, such as Alzheimer's disease, frontotemporal dementia, and Parkinson's disease. Investigations from brain imaging studies revealed that Aβ density maps of TBI patients overlapped with those with Alzheimer's disease, and increased Aβ density not only associated with prolonged TBI duration but also associated with decreased white matter integrity. It has been suggested that the axonal injury and cerebrovascular dysfunction due to TBI may associate with the elevated level of Aβ peptides. The increasing accumulation in Aβ due to TBI may contribute to the initiation of the pathological alterations in neurodegeneration diseases. Recent animal studies suggest that acupuncture may promote regeneration of nerves in injured tissues and reduce the concentration of Aβ in brain. Moreover, recent clinical trials also indicate that acupuncture may improve the vascular cognitive impairment due to cerebral small vessel disease. Thus, acupuncture treatment on TBI may not only be of benefit for the TBI recovery but also act to interrupt the pathological changes in these neurodegenerative diseases.

03

Conditions studied

  • Neurodegenerative Diseases

Keywords

  • Acupuncture
  • Traumatic Brain Injury
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. age ≥ 20 years old
  2. GCS score > 8
  3. loss of consciousness \< 24 hr
  4. the physical condition is suitable for acupuncture treatment
  5. having adequate competency for understanding the study and a willingness to sign the written forms
  6. be able to commence the acupuncture intervention within 2 weeks after TBI diagnosis

Exclusion criteria

Exclusion Criteria:

  1. medical history of neurological, cardiovascular events, e.g., epilepsy, stroke, major depression or anxiety
  2. a history of the mental disorder, e.g., major depression or anxiety
  3. other major medical conditions, e.g., active cancer, uncontrolled diabetes, amputation
  4. receipt of acupuncture within the 6 months prior to study entry
  5. patients with pacemaker or metal graf
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
76 participants (estimated)

Study arms

  • Experimental
    acupuncture treatment group

    Disposable acupuncture needles will be inserted into acupoints for a depth of 20-30 mm in a direction oblique or parallel to the surface. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes. Acupuncture points: Baihui(DU20), Sishencong(EM1), Hegu(LI4), Taichong(LR3)

    Procedure: Acupuncture

  • Placebo comparator
    sham acupuncture treatment group

    Streitberger's non-invasive placebo acupuncture needles will be used in the control group; blunt-tipped needles will touch the skin quickly without being inserted. To ensure allocation concealment, all needles will be affixed with plastic O-rings and adhesive tapes. Acupuncture points: Baihui(DU20), Sishencong(EM1), Hegu(LI4), Taichong(LR3)

    Procedure: Acupuncture

Interventions

  • ProcedureAcupuncture

    20 minutes of acupuncture treatment, twice a week for 2 weeks. Acupoints will be manually stimulated every 10 minutes.

06

What researchers measure

Primary outcomes

  1. plasma levels of Aβ peptide

    Decreased plasma levels of Aβ peptide

    Time frame: After 2-week acupuncture treatment interva

  2. plasma levels of tau

    Decreased plasma levels of tau

    Time frame: After 2-week acupuncture treatment interva

  3. plasma levels of glial fibrillary acidic protein (GFAP)

    Decreased plasma levels of glial fibrillary acidic protein (GFAP)

    Time frame: After 2-week acupuncture treatment interva

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2023; primary completion for Jul 2026, 35 months later.

Of 75 non-industry interventional studies with no phase under Neurodegenerative Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 57. This study's planned 35 months is close to that.

Counting every sponsor, half of 82 studies reached it within 35 months; a quarter within 11 and three quarters within 67.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2023
First posted
May 3, 2023
StartEst.
Aug 1, 2023
Primary completionEst.
Jul 31, 2026
CompletionEst.
Jul 31, 2026
Last update
May 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05839132
Responsible party
Yu-Chen Lee (professor, China Medical University Hospital) — Principal investigator
First posted
May 3, 2023
Start date
Aug 1, 2023 (estimated)
Primary completion
Jul 31, 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
May 3, 2023

Study contacts

Yu-Chen Lee, Ph.D
Contact
d5167@mail.cmuh.org.tw
+886-975-682023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion